This contradicts days of intense speculation that sent shockwaves through global biotech markets. There never was a deal to be done, and there are no discussions between the companies," the anonymous source stated to Reuters. This reversal came after AstraZeneca experienced a 9% drop when initial merger speculation surfaced over the weekend. The anonymous source emphasized that under Britain's stringent market abuse regulations, any genuine merger discussions of this magnitude would have legally required immediate public disclosure. The potential transaction reignited concerns about the loss of UK corporate champions and spurred antitrust concerns from regulatory authorities.